Sanuwave Health, Inc. (SNWV) Appoints Dustin Libby as EVP of Commercial Operations
Get Alerts SNWV Hot Sheet
Join SI Premium – FREE
Sanuwave Health, Inc. (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the hiring of Dustin Libby as its EVP of commercial operations.
Libby brings 20 years of medical device experience focused on commercial growth, sales operations, and launch execution.
His career includes leadership roles at Abiomed where, as director of commercial operations, he helped scale a $15M surgical business to over $500M in revenue. Other roles include experience at Smith & Nephew, Arthrex, and Hill-ROM, where he directed sales enablement, operational strategy, KOL development, and product launches across multiple therapeutic areas. This depth of experience positions Dustin to drive scale, agility, and growth at Sanuwave.
Dustin earned his B.S. degree in Product Design & Development at Keene State College
“We are pleased to welcome Dustin to Sanuwave at this exciting time in our growth plans,” said CEO Morgan Frank. “He brings the experience in scaling teams and systems and the ‘run through walls’ energy that will see us through the next evolutions of our plans to extend our leadership in the wound care market.”
“I am thrilled to join Sanuwave and leverage my two decades of medical device experience to drive significant commercial growth. I'm driven to scale our innovative technologies to reach more patients and make a meaningful impact on their lives."
Dustin began work at Sanuwave on June 3, 2025.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pizza Hut CEO Aaron Powell resigns
- DigitalBridge to delist preferred stock from NYSE ahead of SoftBank deal
- Agilent Technologies filed for proposed debt offering
Create E-mail Alert Related Categories
Corporate News, Management ChangesRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, FDA, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share